Nyxoah (NASDAQ:NYXH) Posts Quarterly Earnings Results, Misses Estimates By $0.20 EPS

Nyxoah (NASDAQ:NYXH) posted its quarterly earnings data on Thursday. The company reported ($0.67) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.47) by ($0.20), Zacks reports. The business had revenue of $8.76 million during the quarter, compared to analysts’ expectations of $8.64 million. Nyxoah had a negative return on equity of 218.59% and a negative net margin of 443.16%.

Nyxoah Trading Down 7.1%

Shares of NYXH stock traded down $0.10 on Thursday, reaching $1.31. 168,758 shares of the company’s stock were exchanged, compared to its average volume of 148,589. The company has a current ratio of 0.99, a quick ratio of 0.88 and a debt-to-equity ratio of 0.53. The company’s fifty day simple moving average is $1.69 and its 200 day simple moving average is $2.96. The stock has a market capitalization of $50.78 million, a PE ratio of -0.52 and a beta of 1.62. Nyxoah has a 52 week low of $1.26 and a 52 week high of $8.59.

Hedge Funds Weigh In On Nyxoah

Several hedge funds and other institutional investors have recently modified their holdings of NYXH. Heights Capital Management Inc. purchased a new stake in Nyxoah in the fourth quarter valued at approximately $3,575,000. Deutsche Bank AG grew its stake in Nyxoah by 40.0% during the 4th quarter. Deutsche Bank AG now owns 35,000 shares of the company’s stock valued at $161,000 after acquiring an additional 10,000 shares in the last quarter. Citadel Advisors LLC purchased a new stake in shares of Nyxoah in the third quarter valued at approximately $98,000. Bank of America Corp DE increased its holdings in shares of Nyxoah by 152.7% in the third quarter. Bank of America Corp DE now owns 19,878 shares of the company’s stock valued at $91,000 after purchasing an additional 12,012 shares during the last quarter. Finally, Raymond James Financial Inc. lifted its position in Nyxoah by 35.6% during the third quarter. Raymond James Financial Inc. now owns 12,762 shares of the company’s stock worth $59,000 after buying an additional 3,353 shares in the last quarter.

Analyst Ratings Changes

A number of research analysts have recently weighed in on the company. Weiss Ratings cut Nyxoah from a “sell (d-)” rating to a “sell (e+)” rating in a research report on Friday, May 22nd. Stifel Nicolaus decreased their target price on shares of Nyxoah from $5.00 to $3.00 and set a “hold” rating on the stock in a research note on Wednesday, June 17th. Oppenheimer set a $4.00 price target on shares of Nyxoah in a report on Thursday. Robert W. Baird set a $2.31 price target on shares of Nyxoah in a research report on Thursday. Finally, Piper Sandler reissued an “overweight” rating and issued a $6.00 price objective (down from $7.00) on shares of Nyxoah in a research note on Thursday. Two equities research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has issued a Sell rating to the company. According to MarketBeat, the company presently has an average rating of “Hold” and an average target price of $5.26.

Nyxoah Company Profile

Nyxoah SA, headquartered in Mont-Saint-Guibert, Belgium, is a medical technology company focused on neuromodulation therapies for sleep?disordered breathing. Established in 2018, the company’s primary offering is the Genio® system, a minimally invasive bilateral hypoglossal nerve stimulator designed to treat moderate to severe obstructive sleep apnea (OSA). By electrically stimulating the genioglossus muscle, the device helps maintain airway patency during sleep, reducing apnea events and improving overall sleep quality.

The Genio system comprises a small, implantable stimulator positioned submentally and an external activation unit worn by the patient.